Backers included RA Capital Management, Boxer Capital of the Tavistock Group, Frazier Healthcare Partners, Venrock Healthcare Capital Partners and Janus Henderson Investors. To date, Sojournix has raised a total of $70m in capital, including $7m in a Series A financing, $19m in a Series B financing and $44m in this Series C financing.
The company intends to use the funds to advance SJX-653, a novel, potent, and selective neurokinin-3 (NK3) receptor antagonist in clinical development as a once-daily non-hormonal treatment for menopausal vasomotor symptoms (commonly referred to as “hot flashes”).
Led by Dan Grau, President, CEO, and co-founder, Sojournix is advancing SJX-653, a selective NK3 antagonist in clinical development as a once-daily non-hormonal therapy for moderate to severe vasomotor symptoms (commonly called “hot flashes”) due to menopause.
Acquired through an asset purchase transaction with H. Lundbeck A/S in 2017, SJX-653 is currently progressing in Phase 1 clinical studies.
FinSMEs
03/01/2019